The firm, which had earlier hired ex-UBS India chief Manisha Girotra, accounted for six per cent market share, with deals worth $2.12 billion. Moelis’ success has come in a shrinking market — the value of deals dropped to $32.2 billion in 2013 from $44.2 billion a year ago.
“In the US, the M&A environment has come back, but for the rest of the world, it has been quite thin; so, if you are lucky enough to be in one or two of the large trades, you have managed to capture market share,” says Girotra. “I would like a more robust M&A platform for the country,” she adds.
Moelis is the second international firm for which Girotra is building operations from scratch. Earlier, she was the face of Swiss bank UBS in India, spending 17 years there. At UBS, she negotiated many big-ticket deals, including Vodafone’s acquisition of Hutchison Essar, United Spirit’s buyout of Whyte & Mackay and Hindalco’s acquisition of Novelis.
Now, when she is competing with investment banking giants such as UBS and Bank of America Merrill Lynch, backed by their huge balance sheets, she draws inspiration from the David and Goliath biblical tale. “We are dealing with a big bulge. So, we draw on global resources and bring together the team quickly,” says Girotra, who has a 12-member strong team in India. “Also, our executions are done by the same partner that originates the deal; so, we do not have the factory approach we need to get into the next deal. That is what we bring and that is what people are liking.”
The firm now plans to go public in the US this year, it also distributed $35 million to staff and investors in its first ever cash distribution. Globally the firm is ranked 11 in the league table with a 5.4% market share and credits for deals worth $134 billion. Some of the prominent deals internationally are the sale of ketchup maker Heinz to Berkshire Hathway in $27.4 billion deal last year.
The firm’s success in India lies in its strength of finding most suitable international buyers for the assets of Indian promoters. Moelis advised Bangalore-based Strides Acrolab for the sale of their injectibles business Agila Specialties to the US based Mylan for $1.6 billion. Global investment bank Jefferies was also a co-banker to Strides for the deal.
It was also a banker for the Financial Technologies, the dominant shareholder in crisis-hit spot exchange NSEL, in selling its subsidiary Singapore Mercantile Exchange to the US-based InterContinental Exchange for $150 million.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)